On July 15, Novo Nordisk (China) Pharmaceutical Co., LTD. (hereinafter referred to as Novo Nordisk) and China Resources Pharmaceutical Group Co., LTD. (hereinafter referred to as China Resources Pharmaceutical) announced that, based on the Letter of intent signed by the two parties, Novo Nordisk and China Resources 39 Pharmaceutical Co., LTD. (hereinafter referred to as: The partnership, which will take effect on August 1, 2020, aims to further enhance the accessibility of NOZet ® in China and benefit more Chinese patients.
In this cooperation, CR 39 will be responsible for the academic promotion of Norze ® across the country, and its wholly-owned subsidiary, CR Beimao Pharmaceutical Management Co., Ltd. will be responsible for the specific implementation work. Novo Nordisk Headquarters remains the owner of Norze ®, the Marketing Authorization Holder (MAH), and will continue to be responsible for the production of Norze ® products, lead the medical strategy and medical interactions, and provide full patient support through the patient hotline. With Etonovo and Nord's decades of innovation and experience in the field of recombinant human growth hormone, and China Resources Pharmaceutical's high-quality academic promotion capabilities and extensive commercial network in the field of pediatrics, the two parties will combine high-quality resources to jointly consolidate and expand the academic promotion coverage network of Norze ®, further expand its accessibility, and provide high-quality treatment options for medical professionals. Make it easier for patients to access quality products developed and manufactured by Novo Nordisk.
In response to the unmet needs in the field of nanosomia in China, Novo Nordisk continues to introduce better and better drugs and injection devices to improve patient adherence and treatment outcomes by enhancing patient medication experience. The two sides will take this cooperation as an opportunity to continue to layout the growth and development field. As Novo Nordisk's second largest market in the world, Greater China occupies an important strategic position in the company's global landscape. Novo Nordisk will continue to deeply cultivate the Chinese market, increase investment, and better serve Chinese patients.
Novo Nordisk Global Senior Vice President and President of Greater China, Ms. Xiaping Zhou, said: "Innovation and collaboration are the cornerstones of our efforts to transform diabetes and other serious chronic diseases in China. As a 'patient-centered' company, we always look at unmet patient needs and are committed to exploring more effective collaborative models to bring quality and innovative treatments to doctors and patients. We are delighted to partner with China Resources 39, a subsidiary of China Resources Pharmaceutical, to jointly improve the accessibility of high-quality innovative medicines to benefit more children with nanosomia in China and improve their quality of life."
Mr. Qiu Huawei, President of China Resources Sanjiu, said, "NOzEUR ® is a leading global growth hormone brand, and its efficacy and safety are widely recognized by doctors and patients. Relying on Novo Nordisk's deep experience in the growth hormone field and our extensive channel network, we will achieve long-term commercial win-win through innovative models to bring this imported original drug, which has benefited many patients around the world, to more patients in need of help in China."
As the world's leading biopharmaceutical company and a leading domestic listed company in the pharmaceutical and health industry, Novo Nordisk and China Resources Pharmaceutical will give full play to the advantages of both sides through this cooperation, fulfill the commitment of "patient-centered", bring more high-quality innovative medicines to Chinese patients, improve the accessibility of medicines, and jointly contribute to the realization of the goals of the Healthy China 2030 plan.